2m 2m 2m 2m 2m 2m 2m
ACRIVON THERAPE (ACRV)
NASDAQ
$1.51-$0.005 (-0.33%)
Price as of Jun 03, 2026 7:43 PM EDT- $68.5MMarket Cap
- 35.34%1-Year Change
- BiotechnologyIndustry
ACRIVON THERAPE (ACRV)
$1.51-$0.005 (-0.33%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | -100,000 N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 +100.00% | -100,000 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -60.0M -6.25% | -64.0M +39.04% | -46.0M N/A | 0 N/A | |
Depreciation and Amortization Expense | 1.4M +34.79% | 1.0M +87.69% | 536,000 +47.25% | 364,000 N/A | |
Total Operating Expenses | 84.1M -5.70% | 89.2M +32.93% | 67.1M +105.48% | 32.7M N/A | |
Operating Profit | -84.1M -5.70% | -89.2M +32.93% | -67.1M +105.48% | -32.7M N/A | |
Interest Income | N/A N/A | N/A N/A | 7.0M N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 -100.00% | 7.0M N/A | 0 N/A | |
Total Nonoperating Income and Expense | 6.2M -28.16% | 8.6M +28.71% | 6.7M +350.67% | 1.5M N/A | |
Income before Taxes | -84.1M -5.70% | -89.2M +32.93% | -67.1M +105.48% | -32.7M N/A | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -77.9M -3.29% | -80.6M +33.40% | -60.4M +93.76% | -31.2M N/A | |
Net Income from Continuing Operations Applicable to Common | -77.9M -3.29% | -80.6M +33.40% | -60.4M +93.76% | -31.2M N/A | |
Basic EPS and Net Income | -2.02 -15.13% | -2.38 -13.14% | -2.74 -63.76% | -7.56 N/A | |
Diluted EPS and Net Income | -2.02 -15.13% | -2.38 -13.14% | -2.74 -63.76% | -7.56 N/A | |
Basic Weighted Average Shares | 38.5M +13.96% | 33.8M +53.06% | 22.1M +435.63% | 4.1M N/A | |
Diluted Weighted Average Shares | 38.5M +13.96% | 33.8M +53.06% | 22.1M +435.63% | 4.1M N/A | |
Balance Sheet | |||||
Cash and Cash Equivalents | 41.5M +4.22% | 39.8M +10.56% | 36.0M +22.01% | 29.5M N/A | |
Short-Term Investments | 77.1M -44.81% | 139.7M +52.73% | 91.4M -6.91% | 98.2M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 118.6M -33.93% | 179.5M +40.82% | 127.5M -0.23% | 127.8M N/A | |
Total Current Assets | 120.4M -33.69% | 181.6M +40.05% | 129.7M -1.82% | 132.1M N/A | |
Accumulated Depreciation | 3.3M +69.11% | 2.0M +105.23% | 956,000 +127.62% | 420,000 N/A | |
Property and Plant and Equipment and Net | 4.9M +9.35% | 4.5M +28.51% | 3.5M +66.30% | 2.1M N/A | |
Total Long-Term Assets | 1.7M +0.36% | 1.6M -55.84% | 3.7M +78.30% | 2.1M N/A | |
Total Assets | 129.7M -34.02% | 196.6M +42.18% | 138.3M -23.71% | 181.2M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 15.7M -9.00% | 17.2M +29.40% | 13.3M +104.16% | 6.5M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 1.5M -40.61% | 2.6M -35.59% | 4.0M -5.12% | 4.2M N/A | |
Total Liabilities | 17.2M -13.14% | 19.8M +16.00% | 17.1M +58.78% | 10.8M N/A | |
Retained Earnings | -274.9M +39.55% | -197.0M +69.19% | -116.4M +107.77% | -56.0M N/A | |
Total Stockholders Equity | 112.5M -36.35% | 176.8M +45.87% | 121.2M -28.91% | 170.5M N/A | |
Total Shares Outstanding | 31.6M +1.34% | 31.2M +38.67% | 22.5M +2.75% | 21.9M N/A | |
Cash Flow | |||||
Cash from Operating Activities | -63.7M -3.05% | -65.7M +54.00% | -42.6M +41.58% | -30.1M N/A | |
Capital Expenditures | 1.7M -39.70% | 2.8M +114.91% | 1.3M -40.54% | 2.2M N/A | |
Cash from Investing Activities | 66.1M +227.68% | -51.8M -202.08% | 50.7M +135.80% | -141.7M N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -749,000 -100.62% | 121.0M +7,888.10% | -1.6M -101.53% | 101.7M N/A | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | 67,103.00% N/A | N/A N/A | |
Return on Assets | -47.75% -0.76% | -48.11% +27.28% | -37.80% N/A | N/A N/A | |
Return on Equity | -53.86% -0.39% | -54.07% +30.57% | -41.41% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 7.69 -27.12% | 10.55 +8.23% | 9.75 N/A | N/A N/A | |
Cash Ratio | 2.65 +14.53% | 2.31 -14.56% | 2.71 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow